openPR Logo
Press release

Acne Vulgaris Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

08-19-2025 08:40 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Acne Vulgaris Pipeline Outlook 2025: Clinical Trial Studies,

DelveInsight's, "Acne Vulgaris Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Acne Vulgaris pipeline landscape. It covers the Acne Vulgaris pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acne Vulgaris pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Acne Vulgaris Treatment Landscape @ Acne Vulgaris Pipeline Outlook [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Acne Vulgaris Pipeline Report

* On July 3, 2025, Biofrontera Bioscience GmbH initiated a study to examine the safety and efficacy of photodynamic therapy (PDT) using Ameluz Registered in combination with the PDT-lamp BF-RhodoLED Registered . The trial compares this approach against a placebo treatment in patients with moderate to severe acne vulgaris.
* On July 9, 2025, Zhejiang Sunshine Mandi Pharmaceutical Co., Ltd . initiated a clinical study to evaluate the safety and efficacy of clascoterone cream, 1%, compared to a vehicle cream. The treatment is applied twice daily over 12 weeks in patients suffering from facial acne vulgaris.
* On July 17, 2025, Sun Pharmaceutical Industries Limited launched a study focusing on Winlevi, recognized as the first topical anti-androgen and sebum inhibitor approved for acne vulgaris. Since no prior trials have investigated its use in combination therapies, this study is assessing Winlevi together with Duac gel to better replicate real-world clinical practice.
* DelveInsight's Acne Vulgaris pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Acne Vulgaris treatment.
* The leading Acne Vulgaris Companies such as Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals and others.
* Promising Acne Vulgaris Pipeline Therapies such as Clascoterone, S6G5T-3, DMT310, ASC40 25mg, GK530G, CD5789 (trifarotene), NVN1000, Afamelanotide, Hydrogen Peroxide, gevokizumab, BLI1100 and others.

Discover groundbreaking developments in Acne Vulgaris Therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Acne Vulgaris Ongoing Clinical Trials Assessment [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acne Vulgaris Emerging Drugs Profile

* Berdazimer sodium (SB 204): Pelthos Therapeutics

SB204 is a first-in-class nitric oxide (NO)-releasing topical treatment monotherapy. The Phase 2b study demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and inflammatory (larger red bumps and pustules) lesions at Week 12 with all doses of SB204 compared to vehicle. SB204 demonstrated excellent cutaneous tolerability with no treatment-related serious adverse events in over 400 dosed subjects to date. Currently, the drug is in Phase III stage of its development for the treatment of acne vulgaris.

* DMT310: Dermata Therapeutics

DMT310 is a lead product candidate, developed from our Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications. It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties. Currently, the drug is in Phase III stage of its development for the treatment of acne vulgaris.

* GT 20029 : Suzhou Kintor Pharmaceuticals

GT-20029 is a small molecule that works on Androgen receptor degradation enhancer's mechanism of action. It is administered through topical route as gel/tincture form. The drug candidate acts by targeting androgen receptor and cereblon (CRBN). It is being developed based on PROTAC (Protein Degradation Targeting Chimera) technology. Currently, the drug is in Phase I stage of its development for the treatment of acne vulgaris.

The Acne Vulgaris Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Acne Vulgaris with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acne Vulgaris Treatment.
* Acne Vulgaris Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Acne Vulgaris Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acne Vulgaris market

Stay informed about the Acne Vulgaris pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Acne Vulgaris Unmet Needs [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Acne Vulgaris Companies

Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals and others.

Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical

Acne Vulgaris Products have been categorized under various Molecule types such as

* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy

Transform your understanding of the Acne Vulgaris Pipeline! See the latest progress in drug development and clinical research @ Acne Vulgaris Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Acne Vulgaris Pipeline Report

* Coverage- Global
* Acne Vulgaris Companies- Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals and others.
* Acne Vulgaris Pipeline Therapies- Clascoterone, S6G5T-3, DMT310, ASC40 25mg, GK530G, CD5789 (trifarotene), NVN1000, Afamelanotide, Hydrogen Peroxide, gevokizumab, BLI1100 and others.
* Acne Vulgaris Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Acne Vulgaris Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Infectious Diseases Research-Access the Full Acne Vulgaris Pipeline Analysis Today! @ Acne Vulgaris Drugs and Companies [https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Acne Vulgaris: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Acne Vulgaris- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Berdazimer sodium (SB 204) : Pelthos Therapeutics
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Early Stage Products (Phase I/II)
* GT 20029 : Suzhou Kintor Pharmaceuticals
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Inactive Products
* Acne Vulgaris Key Companies
* Acne Vulgaris Key Products
* Acne Vulgaris- Unmet Needs
* Acne Vulgaris- Market Drivers and Barriers
* Acne Vulgaris- Future Perspectives and Conclusion
* Acne Vulgaris Analyst Views
* Acne Vulgaris Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acne-vulgaris-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/acne-vulgaris-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Acne Vulgaris Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies here

News-ID: 4150785 • Views:

More Releases from ABNewswire

Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repair Services to Support St. Louis Park Homeowners
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold. Responding to a Growing Need for Water Damage Restoration Property owners across Minnesota are increasingly seeking
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Injury Attorneys Representation in Port Jefferson Station
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents. Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washing Prevents Long-Term Damage in Millsboro DE
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces. In
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection. Market Overview: Understanding Tampa Bay Remodeling Investment Trends Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.

All 5 Releases


More Releases for Acne

Expanding Acne Rates Support Global Anti-Acne Dermal Patch Market Expansion
As per a new market research report launched by Inkwood Research, the Global Anti-Acne Dermal Patch Market is expected to reach $971.37 million by 2032, projecting a CAGR of 7.32% during the forecast period, 2023-2032. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/anti-acne-dermal-patch-market/?utm_source=PaidPRNew&utm_medium=OpenPR&utm_campaign=InkwoodPR This insightful market research report by Inkwood Research focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. The report covers all the
Expanding Acne Rates Support Global Anti-Acne Dermal Patch Market Expansion
As per a new market research report launched by Inkwood Research, the Global Anti-Acne Dermal Patch Market is expected to reach $971.37 million by 2032, projecting a CAGR of 7.32% during 2023-2032. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/anti-acne-dermal-patch-market/?utm_source=PaidPRNew&utm_medium=OpenPR&utm_campaign=InkwoodPR This insightful market research report by Inkwood Research focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. The report covers all the aspects of this comprehensive
Growing Acne Incidences Benefiting Global Anti-Acne Dermal Patch Market Developm …
As per a new market research report launched by Inkwood Research, the Global Anti-Acne Dermal Patch Market is expected to reach $971.37 million by 2032, projecting a CAGR of 7.32% during 2023-2032. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/anti-acne-dermal-patch-market/?utm_source=PaidPRNew&utm_medium=OpenPR&utm_campaign=InkwoodPR This insightful market research report by Inkwood Research focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. The report covers all the aspects of this comprehensive
Expanding Acne Rates Support Global Anti-Acne Dermal Patch Market Expansion
As per a new market research report launched by Inkwood Research, the Global Anti-Acne Dermal Patch Market is expected to reach $971.37 million by 2032, projecting a CAGR of 7.32% during 2023-2032. Refer to the Report Summary Here: https://inkwoodresearch.com/reports/anti-acne-dermal-patch-market/?utm_source=PaidPRNew&utm_medium=OpenPR&utm_campaign=InkwoodPR This insightful market research report by Inkwood Research focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. The report covers all the aspects of
Rising Cases of Acne Boosting Professional Acne Treatment Market Growth
Factor such as the rising cases of acne, surging adoption of acne treatments, growing healthcare spending, increasing disposable income, sedentary lifestyle, strong product pipeline, and mounting number of research programs are expected to propel the professional acne treatment market at a CAGR of 7.6% during 2020–2030. According to P&S Intelligence, the market size is expected to reach $13,124.5 million by 2030 from $6,298.9 million in 2020. Moreover, the market is
Global Market Study on Acne Treatment Inflammatory Acne Segment Anticipated.
The global acne treatment market is stagnant in terms of incremental innovation as most players are investing in product reformulation instead of new product development. The analysts of Persistence Market Research have come up with a new publication titled “Acne Treatment Market: Global Industry Analysis and Forecast, 2017 – 2025,” and have observed that the North America region is expected to witness significant growth in market revenue due to rising affinity